Recombinant Varicella Zoster Virus Glycoprotein E Antigen
Recombinant Varicella Zoster Virus Glycoprotein E Antigen Uses, Dosage, Side Effects, Food Interaction and all others data.
Recombinant zoster vaccine, manufactured as the product Shingrix by GlaxoSmithKline, is an adjuvanted non-live recombinant vaccine indicated for prevention of shingles. First approved in October 2017 by the Food and Drug Administration, Shingrix is the preferred vaccine for preventing varicella zoster infection in people aged 50 years and older, replacing Zostavax as first line therapy.
Herpes zoster, also known as shingles, is caused by a reactivation of Varicella Zoster Virus (VZV), the virus that commonly causes Chickenpox in childhood. Following initial infection of VZV and resolution of Chickenpox as a child, VZV then lies dormant within the dorsal root ganglion of the central nervous sytem. Decades later, when the body's immune system weakens with age, VZV is able to reactivate and descend through the nerve cells to the surface of the skin where it causes a painful blistering rash. Risk factors for developing shingles include old age, with rates increasing substantially in person's over the age of 50, low immune function or immunosuppression, psychological stress, and diabetes. Person's living with HIV or cancer, those taking immunosuppressants, and transplant recipients are particularly at risk .
One of the most common complications associated with shingles is the development of Post-Herpetic Neuralgia (PHN), a persistant severe nerve pain that develops as a result of chronic pain from shingles lesions. PHN can last for days, months, or even years following resolution of shingles. Other complications also include bacterial infection, spread of the shingles rash to the eye (herpes zoster ophthalmicus) or ear, nerve palsies, or spread of VZV to non-immune persons via contact with varicella lesions.
Table Of contents
| Trade Name | Recombinant Varicella Zoster Virus Glycoprotein E Antigen |
| Generic | Varicella zoster vaccine (recombinant) |
| Varicella zoster vaccine (recombinant) Other Names | gE recombinant Varicella zoster virus (VZV) glycoprotein E, gE: Recombinant Varicella Zoster Virus (VZV) glycoprotein E, Recombinant Varicella zoster virus (VZV) glycoprotein E, Recombinant varicella zoster virus glycoprotein E antigen |
| Type | |
| Groups | Approved, Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Shingrix vaccine is indicated for the prevention of herpes zoster (shingles) in adults aged 50 years and older.
Recombinant Varicella Zoster Virus Glycoprotein E Antigen is also used to associated treatment for these conditions: Herpes Zoster
How Recombinant Varicella Zoster Virus Glycoprotein E Antigen works
Shingrix provides protection against Herpes Zoster reactivation by eliciting an immune response to Varicella Zoster Virus (VZV). The main immunological component of Shingrix vaccine is glycoprotein E (gE), a protein found on the surface of varicella zoster virus (VZV). Immune exposure to gE protein stimulates the development of anti-gE antibodies, and therefore adaptive immunity to VZV . The adjuvant system, AS01B, is also included in Shingrix to enhance the immunological response to the vaccine leading to longer lasting and greater immunogenicity to the herpes zoster virus .
Innovators Monograph
You find simplified version here Recombinant Varicella Zoster Virus Glycoprotein E Antigen
